Clinical Approach to Autoimmune Epilepsy

Yoonhyuk Jang, Dong Wook Kim, Kwang Ik Yang, Jung-Ick Byun, Jong-Geun Seo, Young Joo No, Kyung Wook Kang, Daeyeong Kim, Keun Tae Kim, Yong Won Cho, Soon-Tae Lee on behalf of the Drug Committee of Korean Epilepsy Society

Department of Neurology, Seoul National University Hospital, Seoul, Korea
Department of Neurology, Konkuk University School of Medicine, Seoul, Korea
Department of Neurology, Springchungyung College of Medicine, Cheonan Hospital, Cheonan, Korea
Department of Neurology, Kyunghee University Hospital at Gangdong, Seoul, Korea
Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea
Department of Neurology, Samsung Medical Center, Daejeon, Korea
Department of Neurology, Chonnam National University Medical School, Gwangju, Korea
Department of Neurology, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea
Department of Neurology, Keimyung University Dongsan Medical Center, Daegu, Korea

INTRODUCTION

Autoimmune epilepsy is a newly emerging area of epilepsy. The concept of “autoimmune” as an etiology has recently been revisited thanks to advances in autoimmune encephalitis and precision medicine with immunotherapies. Autoimmune epilepsy presents with specific clinical manifestations, and various diagnostic approaches including cerebrospinal fluid analysis, neuroimaging, and autoantibody tests are essential for its differential diagnosis. The diagnosis is often indeterminate despite performing a thorough evaluation, and therefore empirical immunotherapy may be applied according to the judgment of the clinician. Autoimmune epilepsy often manifests as new-onset refractory status epilepticus (NORSE). A patient classified as NORSE should receive empirical immunotherapy as soon as possible. On the other hand, a more-cautious, stepwise approach is recommended for autoimmune epilepsy that presents with episodic events. The type of autoimmune epilepsy is also an important factor to consider when choosing from among various immunotherapy options. Clinicians should additionally take the characteristics of antiepileptic drugs into account when using them as an adjuvant therapy. This expert opinion discusses the diagnostic and treatment approaches for autoimmune epilepsy from a practical point of view.

Key Words autoimmune epilepsy, autoimmune encephalitis, NORSE, autoimmune epilepsy treatment, autoimmune epilepsy immunotherapy, refractory status epilepticus.

CLINICAL CLUES OF AUTOIMMUNE EPILEPSY

Prodromal symptoms

Fever, headache, dizziness, insomnia, or upper respiratory infection may present as prodromal symptoms. Short-term fever generally manifests after immunization against self-antigens. A viral infection should be suspected if the fever persists for more than 3 days. However, since viral encephalitis can be followed by autoimmune encephalitis, clinicians need to consider both possibilities depending on the other symptoms and diagnostic test results of the patient.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical course
The clinical course of autoimmune epilepsy has an acute-to-subacute progression. The clinical symptoms aggregate rapidly from onset to nadir during the acute amplification period of the self-reactive lymphocytes. While a viral infection generally stabilizes within 2 weeks by the production of antibodies, autoimmune epilepsy, if not treated by immunotherapy, often progresses to status epilepticus refractory to conventional antiepileptic drugs (AEDs). Some cases of autoimmune epilepsy show spontaneous remission, but in the presence of triggers, it can recur even several years later. NORSE can be the most-severe form of autoimmune epilepsy, and it is defined as a clinical presentation—not a specific diagnosis—in a patient with the new onset of refractory status epilepticus without a clear acute or active structural, toxic, or metabolic cause.

Comorbid symptoms of autoimmune encephalitis
Autoimmune epilepsy is accompanied by altered mental status, psychiatric symptoms, or memory deficits. The presence of comorbid symptoms often indicates a diagnosis of autoimmune encephalitis, with N-methyl-D-aspartate receptor (NMDAR) encephalitis characterized by psychosis, dyskinesia, hypoventilation, and autonomic dysfunction. Faciobrachial dystonic seizure (FBDS) and hyponatremia are unique features in leucine-rich glioma-inactivated protein 1 (LGI1)-antibody encephalitis. Along with refractory status epilepticus, epilepsy partialis continua frequently presents in γ-aminobutyric acid (GABA)-A encephalitis. Patients with glutamic acid decarboxylase (GAD) encephalitis may develop limbic encephalitis (characterized by seizures and memory decline) or other neurologic syndromes such as cerebellitis and stiff-person syndrome. Nonneurologically, the GAD antibody is associated with type I diabetes mellitus.

Tumor
Autoimmune epilepsy can be associated with a tumor as a paraneoplastic syndrome, but association with an incidental tumor is also common. Ovarian teratoma, thymoma, small-cell lung cancer, and neuroendocrine tumors are especially prone to inducing paraneoplastic syndromes, with approximately 40% of NMDAR encephalitis patients having an ovarian teratoma. Additionally, contactin-associated protein-like 2-antibody encephalitis is associated with thymoma in about 5% of patients. Small-cell lung cancer is detected in 70% of patients with GABA-B encephalitis, while lung cancer and thymoma are found in approximately 70% of patients with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) encephalitis. On the other hand, no tumor has been found to be associated with GAD. These observations indicate that clinicians should consider applying cancer screening to patients with autoimmune epilepsy.

NORSE
A multicenter study found the NORSE etiology in about half of the patients (47%), with autoimmune etiologies (37%, comprising 19% nonparaneoplastic and 18% paraneoplastic) being more common than infection (8%). These results indicate that an autoimmune pathogenesis is much more likely than a viral infection in NORSE. Therefore, after performing a thorough evaluation of infection, it is possible to consider NORSE as potentially autoimmune epilepsy requiring active immunotherapy.

DIAGNOSTIC TESTS
Cerebrospinal fluid analysis
Autoimmune encephalitis generally presents with an abnormal cerebrospinal fluid (CSF) profile, including lymphocytic pleocytosis and elevated protein levels. However, an infectious cause must always be excluded. Atypical bacteria such as listeria, tuberculosus, or borrelia can mimic the symptoms of autoimmune epilepsy. The immunoglobulin G (IgG) index and oligoclonal band in the CSF are helpful to confirm the presence of intrathecal antibody synthesis. While the CSF protein in the acute stage is sensitive to active ongoing inflammation, high levels of CSF protein in the chronic stage can indicate remaining inflammation.

Neuroimaging
The findings of brain magnetic resonance imaging (MRI) in patients with certain types of autoimmune encephalitis can vary from normal to T2-weighted hyperintensities in the mesial temporal lobes or multifocal brain lesions. NORSE patients exhibit progressive medial temporal atrophy even after the NORSE stops, which might be due to the initial injury or an ongoing inflammatory process. The hippocampal atrophy that occurs in NMDAR encephalitis is potentially reversible. On the other hand, the hippocampus of patients with LGI1-antibody encephalitis becomes atrophied if immunotherapy is delayed. Multifocal T2-weighted hyperintensities appear in the cortex and subcortex regions of the temporal and frontal lobes in GABA-A encephalitis. 18F-fluorodeoxyglucose positron-emission tomography (18F-FDG PET) reveals remarkable occipital hypometabolism in NMDAR encephalitis as well as prominent hypermetabolism in the hippocampus and basal ganglia in LGI1-antibody encephalitis. Arterial spin labeling perfusion MRI can detect epileptic foci. However, 18F-FDG PET and arterial spin labeling alone cannot reliably distinguish the different causes of
encephalitis. Finally, clinicians should be aware that a certain proportion of patients with autoimmune encephalitis with no detectable antibody have less-severe or even normal brain MRI or 18F-FDG PET findings despite suffering from relatively severe symptoms.

Electroencephalography

There is no specific electroencephalography (EEG) sign for distinguishing the different types of autoimmune epilepsy. Exceptionally, the extreme delta brush has been suggested to be a specific EEG sign of NMDAR encephalitis, and is found in 30% of patients. It is noteworthy that FBDS (the pathognomonic feature of LGI1-antibody encephalitis) is diagnosed based on the phenomenology alone rather than using EEG. FBDS manifests as a brief (<3 seconds) dystonic movement of the arm that also includes the ipsilateral face or the leg. Since EEG reveals nonspecific abnormalities, clinicians should rely on the clinical history and neurologic examinations. Nevertheless, EEG still plays a significant role in detecting seizures and differentiating them from behavioral symptoms or altered mentality in autoimmune epilepsy.

Autoantibody tests

Autoantibody detection provides a confirmatory diagnosis of autoimmune encephalitis, and thus is recommended in all suspected patients. Clinicians should be aware that no definite autoantibody will be present in 40–50% of cases. Autoantibody screening is applied to both the serum and CSF. In NMDAR encephalitis, the disease severity is correlated with the antibody titer in the CSF but not that in the serum. Although the presence of a systemic antibody (thyroid peroxidase antibody and antinuclear antibodies) is not pathogenic, this can indicate the presence of an autoimmune response.

Brain biopsy

A brain biopsy can be the final option for patients who do not respond to empirical immunotherapy. A specimen must be carefully obtained from focal lesions indicated by brain MRI showing contrast enhancement, T2-weighted fluid-attenuated inversion recovery hyperintensity, or high-intensity diffusion-restricted area in diffusion-weighted imaging. Analyzing the biopsy specimen will make it possible to more accurately exclude other etiologies such as lymphoma, primary angiitis of the central nervous system (CNS), demyelinating disease, or other malignancy. Moreover, the composition of infiltrative lymphocytes (e.g., CD3, CD4, CD8, CD20, and CD68) in the specimen provides information about the main immunity type responsible for autoimmune epilepsy, suggesting the immunotherapy target; for example, cyclophosphamide can be administered to a patient with a high-T-cell infiltrative lesion, and a patient who had a CD68+ microglial lesion responded well to anakinra. Nevertheless, a brain biopsy is invasive, and so cases should be selected carefully.

DIFFERENTIAL DIAGNOSIS AND DIAGNOSTIC APPROACH

The two important steps to addressing autoimmune epilepsy are 1) excluding other etiologies and 2) applying empirical treatment during the diagnosis. From the viewpoint of the “autoimmune” etiology, the detailed criteria are well described in the guideline for autoimmune encephalitis, and the definition can be applied to autoimmune epilepsy with various degrees of certainty. The initial approach starts with a detailed history-taking and neurologic examination (see the sections entitled “Prodromal symptoms” and “Clinical course”). The initial diagnostic workups include blood laboratory, EEG, brain MRI, and CSF studies, which include tests for CNS infection and autoantibodies. All of these tests should also consider other causes of epilepsy, such as CNS infection and vascular, neoplastic, metabolic, degenerative, and genetic diseases. Accordingly, a wide variety of diagnostic tests is required for the differential diagnosis (Fig. 1).

The differential diagnosis in cases of viral encephalitis should screen for herpes simplex virus (HSV) 1, HSV2, varicella-zoster virus, Epstein-Barr virus, enterovirus 71, cytomegalovirus, mumps, Japanese/West Nile encephalitis, and measles. Moreover, atypical bacteria such as listeria, Lyme disease (borrelia), tuberculosis, rickettsia, and neurosyphilis can mimic the clinical manifestations of autoimmune epilepsy. Rare infectious agents including Creutzfeldt-Jakob disease, JC virus, HIV, fungi, amoebas, and parasites should also be excluded. In addition to infection, the following vascular causes manifesting as atypical symptoms are often confused with autoimmune epilepsy: vasculitis, embolic infarction, cerebral venous sinus thrombosis, posterior reversible encephalopathy syndrome, strategic infarction, hemiplegic migraine, and duodenal arteriovenous fistula. Brain tumors such as glioma, leptomeningeal seeding, lymphoma, germ-cell tumor and hemophagocytic lymphohistiocytosis, as well as metabolic diseases including metabolic encephalitis, hyperglycemia/hypoglycemia, porphyria, and vitamin deficiencies are other major conditions that show symptoms similar to autoimmune epilepsy and hence need to be considered in the differential diagnosis. Furthermore, degenerative diseases such as Alzheimer’s disease, and developmental diseases such as mitochondrial diseases, schizophrenia, cortical dysplasia, and autism can mimic autoimmune epilepsy. Finally, the side effects of some drugs such as 5-fluorouracil, ifosfamide, and metronidazole can also produce the clinical symptoms of autoimmuno...
Because the results of tests for viruses and autoantibodies can take several days or even weeks to obtain, empirical immunotherapy such as IVIg can be started if initial labs still support autoimmune epilepsy. In these cases, systemic tumors should be screened for and removed when present. When the final results of autoantibody and virus tests are available, the patients can be reclassified into 1) definite autoimmune epilepsy with the responsible autoantibody, 2) autoimmune epilepsy without definite antibody, and 3) non-autoimmune epilepsy, where immunotherapy has no effect.5

**TREATMENT OF AUTOIMMUNE EPILEPSY**

The treatment of autoimmune epilepsy can be categorized into two axes: 1) disease-modifying treatment by immunotherapy and 2) the administration of appropriate AEDs. For precise immunotherapy, careful history-taking, neurologic examinations, and pathomechanism analysis of autoimmune epilepsy are mandatory. The pathomechanism of autoimmune epilepsy can be categorized as shown in Fig. 2. However, the disease spectrum illustrated in Fig. 2 is hypothetical, and the pathomechanism remains largely unknown.

**Therapeutics: immunotherapy** (Table 1)

Current evidence for immunotherapy in autoimmune encephalitis

High-dose steroids and intravenous immunoglobulin (IVIg) have been the initial immunotherapies for autoimmune encephalitis, affecting a broad spectrum of autoimmune responses including humoral and cellular immune reactions (Table 1). However, more than half of the patients do not respond to the initial therapy, in which cases rituximab has been effective as the next treatment of choice. Rituximab improved the prognosis in patients with autoimmune encephalitis regardless of the autoantibody status and whether they responded to the...
Fig. 2. Pathomechanism of autoimmune epilepsy. The pathomechanism of autoimmune epilepsy can be categorized into two axes: the targets of autoimmunity and the types of autoimmunity. For the end of one axis, AE with the detectable antibody is representative of synaptic, limbic, and neuronal damage. NMO, ADEM, and MS are white-matter diseases at the other end of the axis. AE-noDAB and AE with other antibodies, vasculitis, neuro-Behçet disease, and CLIPPERS are on the spectrum along this axis. Most of the diseases are caused by a combination of adaptive autoimmunity and innate autoimmunity. However, CAIDs are mainly caused by an innate autoimmune reaction. ADEM: acute disseminated encephalomyelitis, AE: autoimmune encephalitis, CAIDs: cerebral autoinflammatory diseases, CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, LGI1: leucine-rich glioma-inactivated protein 1, MS: multiple sclerosis, NMDAR: N-methyl-D-aspartate receptor, NMO: neuromyelitis optica, noDAB: no detectable antibody, PCNSA: primary central nervous system angiitis, SREAT: steroid-responsive encephalopathy-associated thyroiditis.

initial treatment. Most (60%) of the nonresponders to the initial immunotherapy showed a favorable outcome after rituximab treatment. Tocilizumab is the next treatment option, showing efficacy in 60% of the patients who did not respond to rituximab. However, approximately 10% of patients with autoimmune encephalitis do not respond well after receiving combined treatment with a high-dose corticosteroid, IVIg, rituximab, and tocilizumab. The optimal management of this group of patients remains unclear, but other drugs that should be investigated include bortezomib, tyrosine kinase inhibitors, and high-dose methotrexate.

Current evidence for immunotherapy in NORSE
Immunotherapy was first applied to NORSE a few years ago. The first case series showed that plasma exchange (PLEX) therapy could stop refractory seizures in patients with NORSE. Combination therapy of high-dose steroid and IVIg was associated with good outcomes in patients with NORSE. High-dose steroid with IVIg or PLEX can be applied to patients with refractory status epilepticus that is strongly suspected to have an autoimmune origin. The available data indicate that a certain proportion of patients with FIRES and NORSE respond well to treatment with high-dose steroids (11% and 15%, respectively), IVIg (both 5%), and PLEX (2% and 6%). However, an analysis of the NORSE etiology showed that while it was caused by infection in only 8% of patients, 52% were cryptogenic and an autoantibody was found in 37%. Thus, immunotherapy is receiving increasing attention as an important treatment option in patients with NORSE.

Consistent with the above-mentioned findings, a child with superrefractory status epilepticus secondary to FIRES exhibited the overproduction of proinflammatory cytokines such as interleukin (IL)-6 and IL-8 in the CSF, and her seizures were controlled by the IL-1 receptor blocker anakinra. There is evidence that the serum and CSF levels of IL-6 are higher in patients with NORSE. Additionally, the IL-6 receptor blocker tocilizumab stopped NORSE in patients who did not respond to the initial immunotherapy; one or two doses (4–8 mg/kg) of tocilizumab dramatically ameliorated NORSE in six out of seven patients. The findings of that study imply that tocilizumab can be the primarily-suggested treatment of choice in certain NORSE patients.

Nevertheless, clinicians should be aware that the evidence supporting immunotherapy against NORSE is not yet strong enough for this to be established as a treatment guideline. The current evidence mostly comes from single-center studies or cases, and so further studies involving larger numbers of patients are still required. However, considering the urgency of treating NORSE, we cautiously suggest that immunotherapy would be a recommendable option to clinicians who otherwise have no choice but AEDs in the practical setting.
| Treatment          | Mechanism                                                                 | Side effect                                                                 | Regimen                                                                 |
|--------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Corticosteroids    | Suppress lymphocyte activation and proinflammatory gene expression        | Systemic infection                                                        | Methylprednisolone via 1-g daily IV infusion for 3–5 days, followed by oral steroid if necessary |
|                    | Expand the Th2 subgroup compared to the Th1 subgroup                       | Psychiatric symptoms (insomnia, depression, agitation, psychosis)          |                                                                        |
|                    |                                                                           | Hyperglycemia                                                              |                                                                        |
|                    |                                                                           | Cushing syndrome                                                           |                                                                        |
|                    |                                                                           | Gastric ulcer                                                              |                                                                        |
|                    |                                                                           | Tremor                                                                     |                                                                        |
|                    |                                                                           | Osteoporosis                                                                |                                                                        |
|                    |                                                                           | Avascular necrosis                                                         |                                                                        |
| IVIg               | Block neonatal FcR, deplete FcR and F(ab’)_2 receptor, inducing deactivation of both innate autoimmunity and adaptive autoimmunity | Elevated liver enzymes                                                     | 400-mg/kg daily IV infusion for 5 days and monthly maintenance if necessary |
|                    |                                                                           | Allergy induction                                                          |                                                                        |
| Plasma exchange    | Clear autoantibodies and other pathologic substances from the plasma      | Catheterization-related side effects (difficult to apply in patients showing irritability and autonomic symptoms) | 1–1.5 plasma-volume exchange for five to seven sessions with a 48-hour interval |
| Rituximab          | Anti-CD20 of B cells                                                       | Systemic infection (viral)                                                 | 375-mg/m² weekly IV infusion for 4 weeks and monthly maintenance if necessary |
|                    |                                                                           | Chronic infection reactivation (HBV, HCV)                                  |                                                                        |
|                    |                                                                           | Lymphopenia                                                                |                                                                        |
|                    |                                                                           | Infusion-related side effects (injection-site reaction, rash)              |                                                                        |
|                    |                                                                           | Elevated liver enzymes                                                    |                                                                        |
| Tocilizumab        | Block IL-6 receptor of lymphocytes                                         | Systemic infection (bacterial)                                             | Initially 4 mg/kg, followed by an increase to 8 mg/kg monthly depending on the clinical response |
|                    |                                                                           | Neutropenia                                                                |                                                                        |
|                    |                                                                           | Thrombocytopenia                                                           |                                                                        |
|                    |                                                                           | Masked fever and C-reactive-protein elevation                             |                                                                        |
|                    |                                                                           | Hyperlipidemia                                                             |                                                                        |
|                    |                                                                           | Elevated liver enzyme                                                     |                                                                        |
| Cyclophosphamide   | Alkylate DNA of actively proliferating lymphocytes                          | Bone-marrow suppression                                                    | 750-mg/m² monthly IV infusion for 3–6 months (dose reduction if necessary) |
|                    |                                                                           | Infertility                                                                |                                                                        |
|                    |                                                                           | Hemorrhagic cystitis                                                       |                                                                        |
|                    |                                                                           | Alopecia                                                                   |                                                                        |
|                    |                                                                           | Cancer risk                                                                |                                                                        |
|                    |                                                                           | Systemic infection                                                         |                                                                        |
|                    |                                                                           | Nausea, vomiting                                                           |                                                                        |
| Anakinra           | Block IL-1 receptor                                                        | Systemic infection                                                         | 100-mg daily SC injection                                               |
|                    |                                                                           | Headache, nausea                                                           |                                                                        |
|                    |                                                                           | Injection-site reaction                                                    |                                                                        |
| Bortezomib         | Inhibit proteasome, targeting IVIg-producing plasma cells                   | Systemic infection                                                         | 1.3 mg/m² bortezomib with 20-mg IV dexamethasone, twice-weekly SC injection for 2 weeks (days 1, 4, 8, and 11), followed by a 10-day rest |
|                    |                                                                           | Neutropenia                                                                |                                                                        |
|                    |                                                                           | Anemia                                                                     |                                                                        |
|                    |                                                                           | Leukopenia                                                                 |                                                                        |
|                    |                                                                           | Neuropathy                                                                 |                                                                        |
| Azathioprine       | Inhibit purine synthesis, suppressing actively proliferating lymphocytes   | Bone-marrow suppression                                                    | Initially 1–1.5 mg/kg once daily or divided twice daily orally, target 2–3 mg/kg/day |
|                    |                                                                           | Teratogenic                                                                |                                                                        |
|                    |                                                                           | Nausea, vomiting                                                           |                                                                        |
| Mycophenolate      | Inhibit purine synthesis, suppressing actively proliferating lymphocytes   | Bone-marrow suppression                                                    | Initially 500 mg twice daily orally, with a target of 1,000 mg twice daily |
|                    |                                                                           | Teratogenic                                                                |                                                                        |
|                    |                                                                           | Nausea, vomiting                                                           |                                                                        |

HBV: hepatitis B virus, HCV: hepatitis C virus, IL: interleukin, IV: intravenous, IVIg: intravenous immunoglobulin, SC: subcutaneous.
How rapidly should immunotherapy be applied in autoimmune epilepsy?

Since NORSE is an emergency condition, immunotherapy should be administered as soon as possible, preferably within hours or (at worst) days. The occurrence of an uncontrolled seizure during an ongoing differential diagnosis can itself be fatal, and so the conventional management of status epilepticus with AEDs or anesthetics is essential. As empirical immunotherapy, IVIg can be the first treatment of choice because it is both effective in autoimmune epilepsy and safe in viral encephalitis. Moreover, the coadministration of antivirals should be considered until the autoimmune etiology is confirmed if there is suspicion of infection and a relatively rapid aggravation of symptoms. If a patient does not fully respond to the initial immunotherapy, clinicians should move to an alternative immunotherapy such as rituximab, tocilizumab, anakinra, or cyclophosphamide. Rituximab, cyclophosphamide, and tocilizumab have demonstrated efficacy in autoimmune encephalitis, while tocilizumab was additionally found to successful in treating NORSE. Moreover, the occurrence of only sporadic seizures in autoimmune epilepsy will give clinicians more time to complete the differential diagnosis, and treatment and immunotherapy can be applied over days and even weeks. The first step is to control seizures by the appropriate administration of AEDs. However, an AED is an adjuvant treatment in autoimmune epilepsy, and few cases of seizure are prevented by an AED alone. The next step is to apply a maximum diagnostic effort. Empirical immunotherapy is often required since it takes days or even weeks for the results to be obtained in the extensive testing required for a differential diagnosis. Therefore, clinicians should fully discuss the diagnosis and treatment approaches with the patient and their caregivers before deciding whether they will apply immunotherapeutics. IVIg and corticosteroids can be administered as the initial step of immunotherapy. If an infectious origin is excluded and the patient does not respond well to the initial treatment, an alternative immunotherapy such as rituximab, tocilizumab, or cyclophosphamide can be considered. No guideline on when to try the next therapy has been established, and hence this currently depends on 1) the response of the patient to the initial immunotherapy and 2) the expected prognosis when the next immunotherapeutics are delayed. It is suggested that rituximab or cyclophosphamide produces better outcomes in patients who have failed to respond to steroids or IVIg. However, further investigations are necessary for the upfront or combined initial combined use of monoclonal antibody immunotherapeutics.

Protocol for immunotherapies

High-dose corticosteroid

Corticosteroids have historically been applied as the initial treatments for a wide range of inflammatory and autoimmune diseases. The recommended regimen for autoimmune epilepsy is a 1,000-mg daily IV infusion for 3–5 days. In situations where the etiology is unclear, such as autoimmune vs. infection, an empirical steroid might aggravate the infection. In addition, steroids can be ineffective against antibody-mediated immune diseases, and so their efficacy in each type of autoimmune encephalitis needs to be investigated systematically. Also, the psychologic side effects of corticosteroids such as delirium, depressive mood, anxiety, and sleep deprivation can also interfere the ability of the clinician to accurately judge the treatment response.

IVIg

IVIg is recommended as a 400-mg/kg daily IV infusion for 5 days. The half-life of IVIg is 21–28 days, and an additional half-dose infusion can be considered after 1 month. The response rate for a single administration of IVIg is unknown due to the lack of prospective studies. IVIg is relatively safe, with transient hepatic enzyme elevation being the most-common side effect, and eosinophilia or allergy can be induced.

PLEX

The recommended regimen of PLEX in autoimmune epilepsy is 1–1.5 plasma-volume exchanges with 5% albumin replacement fluid. The required consecutive sessions can be performed with a 48-hour interval for five times and more according to the patient’s condition. However, the application of PLEX is restricted in patients with autoimmune epilepsy, since they often show irritability and autonomic symptoms that can result in catheterization-related side effects.

Rituximab

Rituximab is a monoclonal antibody binding to CD20 on the surface of B cells. Rituximab has been classified as a second-line therapy, but due to successful outcomes in autoimmune encephalitis, administration of rituximab in combination with steroid or IVIg has recently been considered. Rituximab shortens the recovery time and reduces the relapse rate. While the common recommended regimen is a 375-mg/m² weekly IV infusion for 4 weeks, the dose and interval can be adjusted according to the patient’s condition. Because an infusion reaction is common, premedication is required before administering rituximab. The depletion of memory B cells in hepatitis B carriers means that they need to take a preventive dose of antiviral agents.
Tocilizumab
Tocilizumab is a monoclonal antibody that blocks the cell-surface IL-6 receptors in a broad spectrum of lymphocytes. IL-6 is the critical cytokine for inducing both cellular and humoral immune responses in autoimmunity. In particular, plasma cells need IL-6 for their survival, and so tocilizumab might reduce the bone-marrow burden of pathogenic plasma cells. The recommended regimen is to start with a 4-mg/kg injection followed by increasing the dosage to 8 mg/kg/month depending on the clinical response. Neutropenia is the most-important adverse effect. The mode of action of tocilizumab can reduce both fever and the elevation of C-reactive protein.

Cyclophosphamide
Cyclophosphamide is an alkylating agent against actively proliferating lymphocytes that reduces both the B- and T-cell burdens. It can therefore be a useful treatment option in patients with vasculitis, excessive T-cell infiltration lesion at biopsy, or autoimmune encephalitis with no detectable antibody accompanying prominent T2-weighted changes in MRI. Pulse infusion at 750 mg/m² monthly for 3–6 months (with dose adjustment according to the clinical condition) is more advantageous than oral intake, given that autoimmune encephalitis shows an acute-to-subacute progression. Blood-count monitoring is necessary at 2–3 weeks after the infusion. Infusion for up to six cycles is recommended, depending on the clinical responses of the patient. Because cyclophosphamide affects all proliferating cells, infertility is one of the serious side effects. Leuprolide acetate, a synthetic gonadotropin-releasing hormone analog, should therefore be considered in all female patients of reproductive age in order to protect them against premature ovarian failure during cyclophosphamide therapy.41

Early immunotherapy
Previous studies have shown that the earlier initiation of immunotherapy will result in faster recovery and a better prognosis. The prognosis depends on the depth of autoimmunity and the presence of neuronal damage. In NMDAR encephalitis, although the receptors are regenerated when the disease antibody is removed, delayed immunotherapy will prolong the disease duration and increase morbidity. The autoantibody of LGI1-antibody encephalitis sometimes induces the loss of hippocampal neurons when treatment is delayed.42,43 Autoimmune epilepsy without definite antibody can result in neuronal damage, since the absence of an autoantibody implies the presence of a novel antibody of unknown pathogenesis or other types of immune reaction, such as innate immunity or T-cell activation, instead of the involvement of plasma cells. Therefore, early empirical immunotherapy should be actively considered for these patients. However, since there is always a risk of prescribing empirical immunotherapy to patients without autoimmune encephalitis, the importance of a thorough clinical evaluation and the exclusion of alternative diagnoses cannot be overemphasized.

Duration of immunotherapy
There are insufficient data for establishing a consensus on how long to maintain immunotherapy. The timescale generally depends on how the patient responds to immunotherapy: the clinician can consider applying short-term immunotherapy and monitoring the response if a patient recovers quickly, while in other cases more-aggressive strategies might need to be considered. It is not yet known whether a monthly IVIg-boosting infusion is advantageous and whether the monthly maintenance of rituximab is beneficial for recovery, and so additional randomized trials are needed. Maintenance immunotherapy is necessary in some cases to prevent recurrence.

Choice of disease-modifying immunotherapeutics according to the pathomechanism

Synaptic antibody
The pathogenesis of autoimmune encephalitis caused by synaptic antibodies are mediated by B cells. Thus, therapeutics against B cells can be an efficient strategy for this disease, with IVIg, high-dose corticosteroids, and PLEX being the first treatment of choice for immunotherapy, and rituximab and tocilizumab being the next treatment choices. Cyclophosphamide should be cautiously applied in young patients due to its adverse effect on reproductive organs. If remission is induced, the patient will usually not need maintenance immunotherapy to prevent recurrences, especially if they have been treated with alternative immunotherapies.

Intracellular/paraneoplastic antibody
Intracellular antigens are exposed by cytolysis induced by cytotoxic T cells and complement activation. Thus, the detection of anti-intracellular molecule antibodies indicates that the cellular immune response is the main process in autoimmune encephalitis. The initial immunotherapy in this group of patients involves IVIg and high-dose corticosteroids, which target a broad spectrum of immune responses. Cyclophosphamide and rituximab can be treatment options for alternative immunotherapy. A maintenance immunosuppressant is required if complete remission is not induced. In addition to immunotherapy, eliminating the source autoantigens constitutes another component of the therapy for this group of patients. If autoimmune epilepsy develops in patients with...
malignancy, cancer treatment should be the primary intervention as long as the autoimmune epilepsy is managed adequately. Further research is required into harmonizing chemotherapy and immunotherapy in this situation.

**Autoimmune encephalitis with no detectable antibody in T2-weighted hyperintense or contrast-enhanced lesions**

Other causes of the disease such as vasculitis, lymphoma, other demyelinating diseases, and infectious encephalitis need to be thoroughly evaluated in this group of autoimmune encephalitides. However, most cases are miscellaneous. The considered treatment options can include immunotherapeutics targeting a broad spectrum of immune responses, such as high-dose corticosteroids, IVIg, cyclophosphamide, and methotrexate.

**Autoimmune encephalitis with no detectable antibody and normal MRI findings**

The presence of a clinicoradiologic mismatch in which there is no or only a minimal MRI lesion but severe clinical deterioration is suggestive of antibody-mediated encephalitis. Immunotherapy similar to that for autoimmune encephalitis with a synaptic antibody can be attempted.

**NORSE**

As mentioned above, the active management of status epilepticus according to the standard protocol is the very first treatment step for NORSE. The sequential application of immunotherapies including IVIg, rituximab, tocilizumab, and anakinra should then be cautiously but promptly considered in an hourly and daily fashion (please see the section entitled “How rapidly should immunotherapy be applied in autoimmune epilepsy?”).

**AEDs in autoimmune epilepsy**

Which AED to apply first is decided by the clinician. As a symptomatic treatment, no significant difference has been found among AEDs in the management of seizures in autoimmune epilepsy. Fewer side effects, no drug–drug interactions, and rapid loading of the drug are major considerations when choosing AEDs for autoimmune epilepsy. The candidate first-line treatments are next-generation AEDs such as levetiracetam, lacosamide, perampanel, zonisamide, and pregabalin, with levetiracetam being the most-used drug. Moreover, the specific pathogenesis in each type of autoimmune epilepsy means that certain AEDs would be theoretically preferred or avoided; for example, in NMDAR encephalitis, NMDAR antagonists such as ketamine should be avoided. The safety of perampanel, which is an AMPA antagonist, has not yet been studied in AMPA-receptor encephalitis. On the other hand, GABA-promoting AEDs such as benzodiazepines and barbiturates can be considered in patients with GABA-A encephalitis. However, as discussed below, the side-effect profiles prevent some AEDs from being used in specific situations. The duration of AED use also should be personalized in individual patients, and AEDs can be tapered off when the autoimmune encephalitis is in full remission.

**Drug interactions**

As an adjuvant treatment, AEDs should be chosen carefully so as not to affect the efficacy of certain immunotherapeutics. Since cytochrome P (CYP) hepatic enzyme inducers reduce the blood levels of immunotherapeutics, they must be avoided in patients who have taken high-dose corticosteroids, cyclophosphamide, and oral immunosuppressants. Moreover, the use of valproic acid, a CYP2C9 enzyme inhibitor that enhances the blood level of immunosuppressants, should also be restricted due to bone-marrow toxicity.

**Psychiatric symptoms and memory decline**

Psychiatric symptoms and memory decline are common symptoms in limbic encephalitis, and so AEDs with similar side effects should be avoided as the first choice in these patients. Levetiracetam and perampanel can induce or aggravate psychiatric and behavior abnormalities. If levetiracetam or perampanel is used to control seizures in the acute stage, it will be necessary to switch to other AEDs for long-term maintenance. Topiramate and valproic acid can aggravate cognitive decline in limbic encephalitis.

**Rash**

A rash can occur as an infusion-related symptom of IVIg and rituximab or as a side effect of other immunosuppressants. Thus, oxcarbazepine and lamotrigine have the disadvantage that it is difficult to distinguish whether a rash is an immunotherapy-related symptom or a side effect of the AEDs. In particular, the use of aromatic AEDs has a high risk of idiosyncratic cutaneous reactions in LGI1-antibody encephalitis. In addition, hyponatremia (the side effect of aromatic AEDs) can mimic the symptoms of LGI1-antibody encephalitis. We therefore recommend avoiding the use of aromatic AEDs in LGI1-antibody encephalitis.

**Cytopenia**

Cytopenia is one of the serious side effects of immunotherapies such as rituximab, tocilizumab, and cyclophosphamide. The next immune treatment approach should be delayed until the blood cell counts recover. Valproic acid and oxcarbazepine can also induce cytopenia, and so they must be carefully considered so as not to aggravate this symptom.
CONCLUSION

Considerable progress has been made in the field of autoimmune epilepsy since the discovery of autoimmune encephalitis. In particular, the introduction of various immunotherapy options has made some cases of the disease curable. However, the diagnosis still depends heavily on the individual judgment of the clinician, with autoantibody confirmation tests results being negative in more than half of the patients, and thus requiring this type of diagnosis. In this context, empirical immunotherapy is simultaneously a therapeutic method and a part of the diagnostic approach for autoimmune epilepsy. Clinicians are well aware of the dilemma that although empirical immunotherapy is expensive and has potential critical side effects, it has to be applied as soon as possible to a specific group of patients in order to improve the prognosis. Thus, this review may help in the development of practical treatment approaches for autoimmune epilepsy—the clues for identifying autoimmune epilepsy suggested in this study provide a basic understanding of when to begin empirical immunotherapy. Moreover, a method has been provided for selecting immunotherapy options according to the pathomechanisms of different types of autoimmune epilepsy.

Approximately 15% of patients still do not respond well to immunotherapy treatment, and so future research needs to focus on patients with refractory autoimmune epilepsy. The pathomechanism first has to be clarified in order to determine why current immunotherapies are ineffective. Other therapeutic options including those that target the innate immunity are worth considering. The duration of immunotherapy maintenance should also be addressed. This review is mainly based on evidence gathered from previous studies, but expert opinions are also presented to address certain unknown areas. Further studies are needed to provide supporting data for these expert opinions.

Author Contributions

Conceptualization: all authors. Funding acquisition: Yong Won Cho, Soon-Tae Lee. Methodology: all authors. Project administration: Soon-Tae Lee, Yong Won Cho. Supervision: all authors. Visualization: Yoonhyuk Jang, Soon-Tae Lee. Writing—original draft: Yoonhyuk Jang, Soon-Tae Lee. Writing—review & editing: Yoonhyuk Jang, Soon-Tae Lee.

ORCID iDs

Yoonhyuk Jang https://orcid.org/0000-0002-3346-3357
Dong Wook Kim https://orcid.org/0000-0003-4484-0602
Kwang Ik Yang https://orcid.org/0000-0001-6343-6520
Jung-Ick Byun https://orcid.org/0000-0002-6224-4575
Jong-Geun Seo https://orcid.org/0000-0002-3944-5731
Young Joo No https://orcid.org/0000-0002-0145-5707
Kyung Wook Kang https://orcid.org/0000-0001-9362-8670
Daeyoung Kim https://orcid.org/0000-0001-9056-0017
Keun Tae Kim https://orcid.org/0000-0002-7124-0736
Yong Won Cho https://orcid.org/0000-0002-6127-1045

CONCLUSIONS

The authors have no potential conflicts of interest to disclose.

Acknowledgements

Soon-Tae Lee have an advisory role and received research grants from GC Pharma outside of the current work.

REFERENCES

1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guerrini R, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:512-521.
2. Prüss H, Finke C, Hölte M, Hofmann J, Klingbeil C, Probst C, et al. N-methyl-D-aspartate receptor antibodies in herps simplex encephalitis. Ann Neurol 2012;72:902-911.
3. Leyboldt F, Titulaer MJ, Aguilar E, Walther J, Bönstrup M, Havemeister S, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013;81:1637-1639.
4. Hirsch L, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018;59:739-744.
5. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391-404.
6. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures preceede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892-900.
7. Spatola M, Petit-Pedrol M, Simabukuro MM, Arangue T, Castro FJ, Barcelo Artigues MI, et al. Investigations in GABA A receptor antibody-associated encephalitis. Neurology 2017;88:1012-1020.
8. Lancaster E. The Diagnosis and treatment of autoimmune encephalitis. J Clin Neurol 2016;12:1-13.
9. Titulaer MJ, McCracken L, Gabilondo I, Arangue T, Castro FJ, Barcelo Artigues MI, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015;85:1604-1613.
10. Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, et al. Rituximab therapy maintenance should also be addressed. This review is mainly based on evidence gathered from previous studies, but expert opinions are also presented to address certain unknown areas. Further studies are needed to provide supporting data for these expert opinions.
34. Byun JI, Lee ST, Jung KH, Sunwoo JS, Moon J, Kim TJ, et al. Identification of cerebral perfusion using arterial spin labeling in patients with seizures in acute settings. PLoS One 2017;12:e0173538.

33. Iro MA, Martin NG, Absoud M, Pollard AJ. Intravenous immunoglobulin in neurological diseases. Neurotherapeutics 2016;13:34–46.

32. Somers EC, Marder W, Christianson GM, Ognerowski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761–2767.

31. Sonderen A, Thijis RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016;87:1449–1456.

30. Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018;141:348–356.

29. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481–1494.

28. Brophy GM, Bell R, Claassen J, Allredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012;17:3–23.

27. Shin YW, Ahn SJ, Moon J, Kim TJ, Jun JS, Byun JJ, et al. Increased adverse events associated with antiepileptic drugs in leucine-rich glioma-inactivated protein 1 encephalitis. Epilepsia 2018;59 Suppl 2:108–112.

26. Li J, Saldivar C, Maganti RK. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure 2018;84:940–945.

25. Shin YW, Lee ST, Kim TJ, Jun JS, Chu K. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol 2018;5:598–605.

24. Lee WJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Arthritis Res Ther 2014;16:217–220.

23. Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013;22:70–73.

22. Dubey D, Pittcock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018;83:166–177.

21. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in a multicentre, population-based prospective study. Lancer Infect Dis 2010;10:835–844.

20. Yoo RE, Yun TJ, Yoon BW, Lee SK, Lee SY, Kang KM, et al. Identification of cerebral perfusion using arterial spin labeling in patients with seizures in acute settings. PLoS One 2017;12:e0173538.

19. Schmitt SE, Pargue K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79:1094–1100.

18. Sunwoo JS. Corticosteroid treatment in autoimmune encephalitis. J Neurol Care 2017;10:60–68.

17. Lünenmann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics 2016;13:34–46.

16. Somers EC, Marder W, Christianson GM, Ognerowski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761–2767.

15. Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018;141:348–356.

14. Iannicola L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttini P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190–195.

13. Ginzler EM, Aranow C. Mycophenolate mofetil in lupus nephritis. Lupus 2005;14:59–64.

12. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783–1792.

11. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958–963.

10. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttini P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190–195.

9. Iannicola L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttini P, Doria A. Mycophenolate mofetil in lupus nephritis. Lupus 2005;14:59–64.

8. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619–1623.

7. Martin ST, Cardwell SM, Naior MD, Gabardi S, Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am J Transplant 2014;14:788–796.

6. Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, Volkov S, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther 2014;8:349–364.

5. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:538–647.

4. Meerts M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118–1125.

3. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783–1792.

2. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958–963.

1. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttini P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190–195.

www.thejcn.com JCN 529